147 related articles for article (PubMed ID: 23355920)
1. Hepatic sarcoidosis complicating treatment-naive viral hepatitis.
Aravinthan A; Gelson W; Limbu A; Brais R; Richardson P
World J Hepatol; 2012 Dec; 4(12):402-5. PubMed ID: 23355920
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
3. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
Hurst EA; Mauro T
Arch Dermatol; 2005 Jul; 141(7):865-8. PubMed ID: 16027302
[TBL] [Abstract][Full Text] [Related]
4. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.
Nishikawa H; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Kita R; Kimura T; Osaki Y
BMC Res Notes; 2012 Mar; 5():135. PubMed ID: 22405406
[TBL] [Abstract][Full Text] [Related]
5. Sarcoidosis and chronic hepatitis C: a case report.
Brjalin V; Salupere R; Tefanova V; Prikk K; Lapidus N; Jõeste E
World J Gastroenterol; 2012 Oct; 18(40):5816-20. PubMed ID: 23155326
[TBL] [Abstract][Full Text] [Related]
6. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
Emara MH; El-Gammal NE; Mohamed LA; Bahgat MM
Virol J; 2010 Nov; 7():324. PubMed ID: 21083926
[TBL] [Abstract][Full Text] [Related]
7. [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
Moudden MK; Ziadi T; Al Bouzidi A; Ouarssani A; Hadri L; El Baaj M
Rev Pneumol Clin; 2014 Dec; 70(6):362-5. PubMed ID: 25131364
[TBL] [Abstract][Full Text] [Related]
8. Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.
Bolukbas C; Bolukbas FF; Kebdir T; Canayaz L; Dalay AR; Kilic G; Ovunc O
Acta Gastroenterol Belg; 2005; 68(4):432-4. PubMed ID: 16432996
[TBL] [Abstract][Full Text] [Related]
9. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
10. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
[TBL] [Abstract][Full Text] [Related]
12. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK; Gad MA; Abd-Ellah MF; Eid MS
J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
[TBL] [Abstract][Full Text] [Related]
14. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
Garnock-Jones KP
Drugs; 2012 Dec; 72(18):2431-56. PubMed ID: 23231027
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
16. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
Fiel MI; Shukla D; Saraf N; Xu R; Schiano TD
Transpl Infect Dis; 2008 Jun; 10(3):184-9. PubMed ID: 17916116
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
Shepherd J; Waugh N; Hewitson P
Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
[TBL] [Abstract][Full Text] [Related]
18. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
Ray G; Pal S; Nayyar I; Dey S
Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
[TBL] [Abstract][Full Text] [Related]
20. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.
Dixit VK; Ghosh JK; Lamtha SC; Kaushik P; Goyal SK; Behera MK; Singh N; Jain AK
J Clin Exp Hepatol; 2014 Jun; 4(2):101-5. PubMed ID: 25755547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
